Viral RNA in Blood as Indicator of Severe Outcome in Middle East Respiratory Syndrome Coronavirus Infection

Technical Appendix

Technical Appendix Table 1. Sensitivity, reproducibility, and inhibitory effect among different specimen types for the Middle East respiratory syndrome coronavirus rRT-PCR*

respiratory syndrome coronavirus TRT-PCR		upE RNA co	ncentration, co	pies/μL RNA	
Specimen,† C _t	1,000	100	10	1	0
Water, Inhibitor-negative control					
Test 1	30.24	32.93	36.54	42.32	ND
Test 2	29.86	33.45	36.31	ND	Not tested
Test 3	30.34	33.45	36.68	ND	ND
Test 4	29.91	33.40	37.44	ND	Not tested
Mean C _t	30.09	33.31	36.74	42.32	ND
Total positive results/total tests	4/4	4/4	4/4	1/4	0/2
0.01% Sodium dodecyl sulfate, Inhibitor-positive control					
Test 1	33.77	36.26	38.36	ND	ND
Test 2	33.44	35.97	41.85	ND	Not tested
Test 3	33.67	37.09	ND	ND	ND
Test 4	33.61	37.23	44.90	ND	Not tested
Mean C _t	33.62	36.64	41.70	ND	ND
Total positive results/total tests	4/4	4/4	3/4	0/4	0/2
RNA extracted from frozen EDTA whole blood					
Test 1	30.66	33.81	36.45	40.19	ND
Test 2	30.60	34.22	37.73	39.44	Not tested
Mean C _t	30.63	34.02	37.09	39.82	ND
Total positive results/total tests	2/2	2/2	2/2	2/2	0/1
RNA extracted from unfrozen EDTA whole blood					
Test 1	30.82	34.47	39.44	ND	ND
Test 2	31.32	34.69	38.56	ND	Not tested
Mean C _t	31.07	34.58	39.00	ND	ND
Total positive results/total tests	2/2	2/2	2/2	0/2	0/1
RNA extracted from plasma of EDTA whole blood					
Test 1	30.37	34.25	36.65	ND	ND
Test 2	30.67	34.79	38.20	ND	Not tested
Mean C _t	30.52	34.52	37.43	ND	ND
Total positive results/total tests	2/2	2/2	2/2	0/2	0/1
RNA extracted from serum of clotted whole blood					
Test 1	30.97	33.57	36.51	ND	ND
Test 2	30.92	35.20	36.67	ND	Not tested
Mean C _t	30.95	34.39	36.59	ND	ND
Total positive results/total tests	2/2	2/2	2/2	0/2	0/1

^{*}C_t, cycle threshold; ND, not detected; rRT-PCR, real-time reverse transcription PCR.

[†]To evaluate the inhibitory effect in RNA from each specimens, the *upE* RNA with known copy numbers was spiked in series of quadruplicated controls and duplicated tests to generate panels of 5 concentrations (1,000, 10, 1, and 0 copies/µL), and the rRT-PCR *upE* was performed afterward.

Technical Appendix Table 2. Viral RNA analyses of Middle East respiratory syndrome coronavirus-infected patients: demographic and clinical features, and disease outcomes, South Korea, 2015*

	rRT-PCR			No. days				,	Days from initial diagnosis to		Respiratory specimen				
	Using EDTA v	whole blood	Using	serum	Virus detection in				Days from symptom onset	specimen s	ampling	Ct from rRT-PCR usir	ng initial specimen		_
Case					blood, EDTA whole		Patient	based on contact	to initial diagnosis using	EDTA whole				Specimen	Hospitalized,
identifier	$upE\uparrow (C_t)$	$N \ddagger (C_t)$	$upE(C_t)$	$N(C_t)$	blood, and/or serum	Outcome	sex/age, y	history	respiratory specimen	blood	Serum	upE	ORF1a	subtype	d
01	Positive (35.34)	Positive (36.37)	Positive (37.32)	Positive (34.62)	Positive	Died	M/71	6	5	1	1	23.45	24.30	Sputum	5
02	Positive (37.81)	Positive (36.35)	Positive (37.63)	Positive (34.74)	Positive	Died	M/56	3	1	5	5	28.56	31.00	Sputum	10
03	Positive (37.38)	Positive (35.81)	Positive (36.38)	Positive (33.78)	Positive	Died	M/86	7	1	1	3	33.19	30.83	Sputum	10
04	Positive (38.07)	Positive (36.70)	Not detected	Positive (35.76)	Positive	Died	F/70	1	12	2	2	19.70	21.00	Sputum	2
05	Positive (37.46)	Positive (36.40)	Positive (36.43)	Positive (34.00)	Positive	Survived	M/68	20	8	1	1	29.35	31.45	Endotracheal	129
														aspirate	
06	Positive (37.63)	Positive (35.62)	Positive (34.24)	Positive (32.93)	Positive	Survived	M/71	1	3	1	1	23.34	23.01	Sputum	43
07	Not detected	Not detected	Positive (38.14)	Positive (38.84)	Positive	Survived	F/75	3	0	3	1	Positive, value not reported	Positive, value not reported	Sputum	21
08	Not detected	Positive (38.04)	Not detected	Not detected	Not detected	Survived	M/79	2	6	1	1	24.44	25.89	Sputum	138
09	Not detected	Not detected '	Not detected	Not detected	Not detected	Died	M/76	1	0	1	1	28.10	28.65	Sputum	16
10	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/63	6	2	0	0	26.23	26.63	Sputum	17
11	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/46	1	2	0	0	29.30	30.45	Sputum	23
12	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/39	3	10	4	4	24.88	25.44	Sputum	18
13	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/23	3	9	2	2	28.40	28.04	Sputum	14
14	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/64	3	2	0	0	30.60	29.70	Sputum	12
15	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	M/86	7	1	1	2	20.14	22.20	Sputum	20
16	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/83	7	10	1	1	33.22	34.21	Sputum	18
17	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/52	5	1	1	1	28.40	28.85	Sputum	50
18	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	M/50	1	4	2	2	32.15	32.58	Sputum	24
19	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/24	3	1	2	2	33.46	33.12	Sputum	15
20	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/24	12	Asymptomatic	1	1	32.79	32.51	Sputum	8
21	Not detected	Not detected	Not detected	Not detected	Not detected	Survived	F/24	7	Asymptomatic	0	0	32.59	32.26	Sputum	13

^{*}C₁, cycle threshold; rRT-PCR, real-time reverse transcription PCR. †rRT-PCR *upE* was originally developed in reference *12*. ‡rRT-PCR *N2* was originally developed in Reference *13*.

Technical Appendix Table 3. Statistical relationships among clinical and molecular diagnostic factors associated with MERS-CoV infection, South Korea, 2015

Association between factors	p value	Statistical test
Blood viral RNA positivity and viral C _t in initial diagnostic lower respiratory	0.312	Mann-Whitney U
specimens		
Blood viral RNA positivity and requirement of oxygen supplementation during the	0.061	2-Tailed Fisher exact
following clinical course		
Differences in age between the blood viral RNA-positive and -negative groups	0.094	Mann-Whitney U
Differences in duration from symptom onset to diagnosis of MERS-CoV infection	0.967	Mann-Whitney U
between the blood viral RNA-positive and negative groups		
Differences in the experience of invasive procedure before the specimens were	0.337	2-Tailed Fisher exact
obtained between the blood viral RNA-positive and -negative groups		
Patient death and the length of time from symptom onset to diagnosis of MERS-	0.559	Mann-Whitney U
CoV infection		

 $^{^{\}star}C_{t}$, cycle threshold; MERS-CoV, Middle East respiratory syndrome coronavirus.